JP Morgan Maintains Overweight on AnaptysBio, Raises Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on AnaptysBio (NASDAQ:ANAB) and raises the price target from $69 to $75.
August 07, 2024 | 5:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on AnaptysBio and raises the price target from $69 to $75.
The increase in the price target from $69 to $75 by a reputable analyst at JP Morgan is a positive signal for investors, indicating confidence in AnaptysBio's future performance. This is likely to result in a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100